Sources are reporting that Celltrion has received clearance from the China Food and Drug Administration (CFDA) to conduct clinical trials of Remsima (infliximab), a biosimilar of Janssen’s Remicade.  This is the first time a non-Chinese company will begin clinical trials of a biosimilar mAb in China.

Remsima is approved in the U.S. and the E.U.